Carol S. Lim

发表

A single mutant, A276S of p53, turns the switch to apoptosis.

Shams Reaz, Mohanad Mossalam, Abood Okal, 2013, Molecular pharmaceutics.

Basics and recent advances in peptide and protein drug delivery.

Carol S. Lim, B. Bruno, Geoffrey D. Miller, 2013, Therapeutic delivery.

Controlling subcellular delivery to optimize therapeutic effect.

Andrew S. Dixon, Mohanad Mossalam, Carol S. Lim, 2010, Therapeutic delivery.

Controlling Protein Compartmentalization to Overcome Disease

Carol S. Lim, James R. Davis, M. Kakar, 2006, Pharmaceutical Research.

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

Gerald C. Chu, L. Chin, Yonghong Xiao, 2012, Cell.

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

Shan Jiang, Lynda Chin, Qiuyun Wang, 2014, Cell.

Inhibition of bcr-abl in human leukemic cells with a coiled-coil protein delivered by a leukemia-specific cell-penetrating Peptide.

Carol S. Lim, B. Bruno, 2015, Molecular pharmaceutics.

Intracellular localization and trafficking of steroid receptors

G. Hager, Carol S. Lim, C. Baumann, 2007, Cell Biochemistry and Biophysics.

The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondria.

Mohanad Mossalam, Abood Okal, Carol S. Lim, 2013, Molecular pharmaceutics.

Changing the Subcellular Location of the Oncoprotein Bcr-Abl Using Rationally Designed Capture Motifs

Andrew S. Dixon, T. Rabbitts, Carol S. Lim, 2011, Pharmaceutical Research.

Application of Thiol-yne/Thiol-ene Reactions for Peptide and Protein Macrocyclizations.

T. Cheatham, Carol S. Lim, B. Bruno, 2017, Chemistry.

Resistant mutations in CML and Ph+ALL – role of ponatinib

Carol S. Lim, B. Bruno, Geoffrey D. Miller, 2014, Biologics : targets & therapy.

The nuclear translocation assay for intracellular protein-protein interactions and its application to the Bcr coiled-coil domain.

Andrew S. Dixon, Carol S. Lim, 2010, BioTechniques.

A Coiled-Coil Mimetic Intercepts BCR-ABL1 Dimerization in Native and Kinase-Mutant Chronic Myeloid Leukemia

M. Deininger, Carol S. Lim, B. Bruno, 2015, Leukemia.

Geldanamycin, an inhibitor of Hsp90, Blocks cytoplasmic retention of progesterone receptors and glucocorticoid receptors via their respective ligand binding domains

Carol S. Lim, M. Kakar, J. Davis, 2006, The AAPS Journal.

Effect of initial subcellular localization of progesterone receptor on import kinetics and transcriptional activity.

Carol S. Lim, Henan Li, M. Fidler, 2005, Molecular pharmaceutics.

Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib.

Mohanad Mossalam, Carol S. Lim, J. E. Constance, 2012, Molecular pharmaceutics.

Solid Phase Synthesis of Mitochondrial Triphenylphosphonium-Vitamin E Metabolite Using a Lysine Linker for Reversal of Oxidative Stress

Mohanad Mossalam, Carol S. Lim, E. Abel, 2013, PloS one.

MULTI-DOMAIN TARGETING OF BCR-ABL BY DISRUPTION OF OLIGOMERIZATION AND TYROSINE KINASE INHIBITION: TOWARDS ERADICATION OF CML

Carol S. Lim, Geoffrey D. Miller, M. Sirch, 2014 .

Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML.

Carol S. Lim, Geoffrey D. Miller, M. Sirch, 2013, Molecular pharmaceutics.

Organelle-specific targeting in drug delivery and design

Carol S. Lim, 2007 .

FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis.

Gerald C. Chu, R. DePinho, S. Signoretti, 2010, Cancer cell.

Delivery of a Monomeric p53 Subdomain with Mitochondrial Targeting Signals from Pro-Apoptotic Bak or Bax

Mohanad Mossalam, Abood Okal, Carol S. Lim, 2014, Pharmaceutical Research.

Direct induction of apoptosis using an optimal mitochondrially targeted p53.

Mohanad Mossalam, Abood Okal, Carol S. Lim, 2012, Molecular pharmaceutics.

Mig-6 controls EGFR trafficking and suppresses gliomagenesis

L. Chin, Yonghong Xiao, C. Brennan, 2010, Proceedings of the National Academy of Sciences.

The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer

Carol S. Lim, B. Wallis, K. Bowman, 2023, Biomolecules.

Targeting malignant mitochondria with therapeutic peptides.

Carol S. Lim, J. E. Constance, Jonathan E Constance, 2012, Therapeutic delivery.

Delivery of drugs and macromolecules to the mitochondria for cancer therapy.

Carol S. Lim, B. Bruno, Malena Rabenau, 2016, Journal of controlled release : official journal of the Controlled Release Society.

Cancer Biology: Some Causes for a Variety of Different Diseases

Shams Reaz, Abood Okal, Carol S. Lim, 2013 .

The androgen receptor and its use in biological assays: looking toward effect-based testing and its applications.

Carol S. Lim, D. Rollins, Amy B. Cadwallader, 2011, Journal of analytical toxicology.

TheAndrogen Receptor and Its Use in BiologicalAssays: LookingToward Effect-BasedTesting and ItsApplications

Carol S. Lim, D. Rollins, Amy B. Cadwallader, 2011 .

p53-Bad* Fusion Gene Therapy Induces Apoptosis In Vitro and Reduces Zebrafish Tumor Burden in Hepatocellular Carcinoma.

K. Evason, Carol S. Lim, E. V. Vander Mause, 2022, Molecular pharmaceutics.

p53-Bad: A Novel Tumor Suppressor/Proapoptotic Factor Hybrid Directed to the Mitochondria for Ovarian Cancer Gene Therapy.

Carol S. Lim, E. V. Vander Mause, Phong Lu, 2019, Molecular pharmaceutics.

Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53

Carol S. Lim, E. V. Vander Mause, Phong Lu, 2019, Journal of Ovarian Research.

Re-engineered p53 Activates Apoptosis In Vivo and Causes Primary Tumor Regression in A Dominant Negative Breast Cancer Xenograft Model

M. Salama, Abood Okal, Carol S. Lim, 2014, Gene Therapy.

Re-Engineered p53 Chimera with Enhanced Homo-Oligomerization That Maintains Tumor Suppressor Activity

T. Cheatham, Abood Okal, Carol S. Lim, 2014, Molecular pharmaceutics.

A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells.

Andrew S. Dixon, Mohanad Mossalam, Abood Okal, 2013, Molecular pharmaceutics.

Abstract 1176: Bypassing the dominant-negative effect of mutant p53 in cancer cells

Mohanad Mossalam, Abood Okal, Carol S. Lim, 2012 .

Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2.

Mohanad Mossalam, Carol S. Lim, James R. Davis, 2013, Molecular pharmaceutics.

Selective Targeting of c-Abl via a Cryptic Mitochondrial Targeting Signal Activated by Cellular Redox Status in Leukemic and Breast Cancer Cells

Carol S. Lim, J. E. Constance, Jonathan E Constance, 2012, Pharmaceutical Research.

PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network.

Gerald C. Chu, L. Chin, A. Protopopov, 2011, Cancer discovery.

Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis.

Andrew S. Dixon, Carol S. Lim, M. Kakar, 2009, Journal of controlled release : official journal of the Controlled Release Society.

Development of an Effective Therapy for CML

M. Deininger, Carol S. Lim, David W. Woessner, 2012 .

Development of an Effective Therapy for Chronic Myelogenous Leukemia

M. Deininger, Carol S. Lim, David W. Woessner, 2011, Cancer journal.

Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer

Carol S. Lim, Ji Hoon Kim, K. Bowman, 2019, Journal of Ovarian Research.

Fast off-rate CD229 chimeric antigen receptor T cells efficiently target multiple myeloma, spare T cells, and exhibit reduced trogocytosis

David P Ng, J. Panse, T. Luetkens, 2021 .

Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.

Carol S. Lim, David W. Woessner, 2013, Molecular pharmaceutics.

Choosing Targets for Gene Therapy

Carol S. Lim, James R. Davis, Karina J. Matissek, 2011 .

Advances in delivery vectors for gene therapy in liver cancer.

Carol S. Lim, E. V. Vander Mause, Phong Lu, 2019, Therapeutic delivery.

Trafficking of nuclear receptors in living cells

G. Hager, Carol S. Lim, C. Elbi, 2000, The Journal of Steroid Biochemistry and Molecular Biology.

Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity.

T. Luetkens, D. Atanackovic, Carol S. Lim, 2022, Trends in biotechnology.

Utilizing the Estrogen Receptor Ligand-Binding Domain for Controlled Protein Translocation to the Insoluble Fraction

Mohanad Mossalam, Carol S. Lim, James R. Davis, 2012, Pharmaceutical Research.

Optimizing the protein switch: altering nuclear import and export signals, and ligand binding domain.

Steven Edward Kern, Carol S. Lim, James R. Davis, 2007, Journal of controlled release : official journal of the Controlled Release Society.

Mapping the Evidence for Opioid-Mediated Changes in Malignancy and Chemotherapeutic Efficacy: Protocol for a Scoping Review

M. Deininger, Carol S. Lim, K. Watt, 2022, JMIR research protocols.

Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.

James C. Robertson, Andrew S. Dixon, T. Cheatham, 2012, Molecular pharmaceutics.

Signal Sequences for Targeting of Gene Therapy Products to Subcellular Compartments: The Role Of CRM1 in Nucleocytoplasmic Shuttling of the Protein Switch

Carol S. Lim, James R. Davis, M. Kakar, 2007, Pharmaceutical Research.

Model system to study classical nuclear export signals

Carol S. Lim, Henan Li, C. Kanwal, 2008, AAPS PharmSci.

Changing the Subcellular Location of the Oncoprotein Bcr-Abl Using Rationally Designed Capture Motifs

Andrew S. Dixon, T. Rabbitts, Carol S. Lim, 2012, Pharmaceutical Research.

p53-Bad* in a Hepatocellular Carcinoma Mouse Model

Carol S. Lim, K. Bowman, Phong Lu, 2023, bioRxiv.

Erratum: Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer (Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer (2014) 158(1) (185–197), (S0092867414007247), (10.1016/j.cell.2014.06.003))

Nora S. Sanchez, Gerald C. Chu, L. Chin, 2019 .

Disruption of Bcr-Abl Coiled Coil Oligomerization by Design*

Andrew S. Dixon, T. Cheatham, Carol S. Lim, 2011, The Journal of Biological Chemistry.

Utilizing the Estrogen Receptor Ligand-Binding Domain for Controlled Protein Translocation to the Insoluble Fraction

Mohanad Mossalam, Carol S. Lim, James R. Davis, 2012, Pharmaceutical Research.

Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity

T. Luetkens, D. Atanackovic, Carol S. Lim, 2023, Science Translational Medicine.

Correlation Among Agonist Dose, Rate of Import, and Transcriptional Activity of Liganded Progesterone Receptor B Isoform in Living Cells

Steven Edward Kern, Carol S. Lim, Henan Li, 2003, Pharmaceutical Research.

Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib.

Mohanad Mossalam, Carol S. Lim, Jonathan E Constance, 2012, Molecular pharmaceutics.

Resistant mutations in CML and Ph+ALL – role of ponatinib

Carol S. Lim, B. Bruno, Geoffrey D. Miller, 2014, Biologics : targets & therapy.

Simultaneous Visualization of the Yellow and Green Forms of the Green Fluorescent Protein in Living Cells

G. Hager, Carol S. Lim, C. Baumann, 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.